October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
A 29-year-old woman with symptoms of both lupus and rheumatoid arthritis improved with specific medications.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
10 citations
,
September 2024 in “Life” Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
2 citations
,
October 2014 in “Orbit” Lacrimal gland inflammation and alopecia areata can happen together due to autoimmune issues.
25 citations
,
October 2010 in “Journal of Hepatology” Budesonide alone is less effective than standard treatment for autoimmune hepatitis.
July 2025 in “Scientific Reports” Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
51 citations
,
August 2015 in “Cochrane library” Methotrexate is not proven to maintain remission in ulcerative colitis.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
January 2024 in “Brazilian Journal of Hair Health” Combining low-level laser therapy with topical corticosteroids effectively improved Lichen Planopilaris symptoms.
January 2024 in “SAGE Open Medical Case Reports” Injectable hyaluronic acid can effectively treat facial lipoatrophy from lupus panniculitis.
12 citations
,
January 1999 in “Journal of Animal Science” Glucocorticoids and thyroid hormones together are essential for fetal fat development.
9 citations
,
February 2018 in “Journal of dermatological treatment” Methotrexate improved skin condition in 64% of patients with generalized granuloma annulare.
45 citations
,
May 2002 in “International Journal of Dermatology” Prednisone may cause multiple skin nodules in lupus patients.
April 2018 in “Journal of Investigative Dermatology” Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.
42 citations
,
March 2015 in “Anais Brasileiros de Dermatologia” Anti-TNF therapy can cause hair loss and skin issues.
May 2026 in “Scholars Journal of Medical Case Reports” Intralesional betamethasone and oral hydroxychloroquine improved hair loss in a woman with frontal fibrosing alopecia.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
28 citations
,
January 2005 in “PubMed” Topical immunomodulators are effective and safe for treating immune-related skin conditions.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
1 citations
,
January 2005 in “PubMed” Steroids affect skin health and healing, offering new treatment options.
August 2002 in “British journal of ophthalmology” Surgical excision is the best treatment for SCC, but intralesional cidofovir might be a viable alternative.
17 citations
,
August 1967 in “JAMA” The rapid corticotropin test is a quick and simple way to diagnose adrenal insufficiency.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
May 2018 in “Dermatologic Surgery” 2 citations
,
January 2023 in “SAGE Open Medical Case Reports” Stopping leflunomide healed the woman's skin ulcers.
4 citations
,
October 2013 in “Botanics Targets and Therapy” The herbal preparation may help manage alopecia by reducing inflammation and boosting the immune response.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.